Back to Search
Start Over
Ceftazidime-Avibactam plus Aztreonam for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria
- Source :
- Antimicrob Agents Chemother
- Publication Year :
- 2022
- Publisher :
- American Society for Microbiology, 2022.
-
Abstract
- This is a retrospective single-center study of 24 patients who received ceftazidime-avibactam plus aztreonam (CZA/ATM) for the treatment of VIM-type-producing Gram-negative bacillus (GNB) infections. The bacteria isolated were Enterobacterales in 22 patients and Pseudomonas aeruginosa in 2. Sixteen out of 19 isolates showed synergistic activity. Two patients presented clinical failure at day 14, and the 30-day mortality was 17% (4/24).
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Antimicrob Agents Chemother
- Accession number :
- edsair.doi.dedup.....e8dfdc958b6312e8ebc070c59ea786fd